Vital Signs - Prefilled Syringes: Injecting the End-Users Perspective


USD 1,500.00

* Required Fields

USD 1,500.00


Be the first to review this product

This issue of Vital Signs, released on May 17, 2010, provides a strategic overview of key issues and trends relating to prefilled syringes in drug delviery. Additionally, a company spotlight is provided for Vanda Pharmaceuticals, a biopharmaceutical company utilizing novel technologies, including genetics and genomics, to discover, develop and commercialize drug candidates for central nervous system (CNS) disorders. Reimbursement and regulatory news from the FDA is also provided for the week of April 26, 2010.

Table of Contents

Vital Signs - Prefilled Syringes: Injecting the End-User’s PerspectiveVital Signs: 17 May 2010This week's issue:

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.